Last reviewed · How we verify
NCT02441660: Capsaicin
Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain
NA trial testing Capsaicin 8% Patch in Spinal Cord Injuries in 11 participants. Completed in 2 May 2022.
31 July 2021
Quick facts
| Lead sponsor | The University of Texas Health Science Center at San Antonio |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 1 April 2016 |
| Primary completion | 31 July 2021 |
| Estimated completion | 2 May 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Capsaicin 8% Patch
- Low Dose Capsaicin 0.025% Well Patch — full drug profile →
Conditions studied
- Spinal Cord Injuries — all drugs for Spinal Cord Injuries →
- Neuropathic Pain — all drugs for Neuropathic Pain →
Sponsor
The University of Texas Health Science Center at San Antonio
Who can join
Adults 18 to 99, any sex, with Spinal Cord Injuries or Neuropathic Pain. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Change in Pain Relief With Visual Analog (VAS) Pain Scale
Time frame: Change in pain at 2,4,6,8, 10 and 12 weeks
The Visual Analog Scale (VAS) was used as the primary outcome measure to quantify pain on a scale of 0-10, with 0 being no pain and 10 being the worst pain. VAS was measured at weeks 2,4,6,8,10 and12 during each 12- week block. -
Change in Quality of Life as Measured by the World Health Organization Quality of Life (WHOQOL-BREF)
Time frame: Every 4 weeks for 12 weeks
The World Health Organization Quality of Life (WHOQOL-BREF) questionnaire is a scale used to assess an individual's perception of their quality of life. Its domains include physical health, psychological health, social relationships, and patient environment. It is scored from 0-100, where lower scores indicate poorer perception of quality of life and higher scores indicate better perception. This -
Change in Spinal Cord Independence Measure (SCIM)
Time frame: Every 4 weeks for12 weeks
The Spinal Cord Independence Measure (SCIM) is a reliable scale that measures proficiency of activities of daily living (ADL's) of patients with spinal cord injuries. (28) It is broken up into four subscales including self-care, respiration and sphincter control, and mobility with a total score combining all 3 outcomes. It is scored from 0-100, where lower numbers indicate more dependence on othe
Sponsor's own description
A prospective case control study to determine the effectiveness and longevity of 8% capsaicin patch(es) in treating neuropathic pain in persons with spinal cord injury. The investigators will study spinal cord injury patients at South Texas Veterans Health Care Systems Spinal Cord Injury inpatient unit and outpatient clinics.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Review of the Treatments for Central Neuropathic Pain.
Sheldon BL, Olmsted ZT, Sabourin S, Heydari E, et al · · 2022 · cited 12× · PMID 36552186 · DOI 10.3390/brainsci12121727 -
Transient Receptor Potential Channels as Key Regulators of Neuroinflammation in Neurological Disorders: Mechanistic Insights, Therapeutic Potentials, and Future Directions.
Guo D, Cai M, Xian Y, Chen Y, et al · · 2025 · cited 1× · PMID 41399206 · DOI 10.1002/cns.70700
Verify or expand the search:
- PubMed search for NCT02441660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Capsaicin 8% Patch
Trials testing the same drug.
- NCT06807164 — Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome · Phase 2 · recruiting
- NCT07122973 — Topographical Distribution of Itch and Pain Receptors · NA · recruiting
- NCT03348735 — Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment · Phase 4 · terminated
Other recruiting trials for Spinal Cord Injuries
Currently open trials in the same condition.
- NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury · NA · recruiting
- NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial · NA · recruiting
- NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury · NA · recruiting
- NCT07488793 — Remote Ischemic Conditioning for PwSCI · NA · recruiting
- NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting
Other The University of Texas Health Science Center at San Antonio trials
Trials by the same sponsor.
- NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
- NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
- NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02441660 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
- Last refreshed: 23 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02441660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing